Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1948-1955

  Floege, Jürgen ^a   Kim, Joseph ^b   Ireland, Elizabeth ^b   Chazot, Charles ^c   Drueke, Tilman ^d   De Francisco, Angel ^e   Kronenberg, Florian ^f   Marcelli, Daniele ^g   Passlick Deetjen, Jutta ^g   Schernthaner, Guntram ^h   Fouqueray, Bruno ⁱ   Wheeler, David C ^j  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b AMGEN LTD   (United Kingdom)

^c Nephrocare Tassin ^*  (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g FRESENIUS MEDICAL CARE   (Germany)

^h KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

ⁱ AMGEN INC   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

calcium; KDOQI; mineral bone disorders; parathyroid hormone; phosphate

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; EUROPE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POPULATION RESEARCH; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT DURATION;

AGED; BONE DISEASES, METABOLIC; CALCIUM; COHORT STUDIES; CREATININE; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALS; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 79957830094     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq219     Document Type: Article

References (33)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
3. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187. (Pubitemid 41623345)
4. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
5. Wald R, Sarnak MJ, Tighiouart Het al. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52: 531-540.
6. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
8. Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44: 16-21.
9. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277. (Pubitemid 37509303)
10. Lacson E Jr,WangW, Hakim RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis 2009; 53: 79-90.
11. Royston P, SauerbreiW. Building multivariable regression models with continuous covariates in clinical epidemiology-with an emphasis on fractional polynomials. Methods Inf Med 2005; 44: 561-571. (Pubitemid 41345381)
12. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007; 26: 5512-5528. (Pubitemid 351193578)
13. Qureshi AR, Alvestrand A, Divino-Filho JC et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 13: S28-S36.
14. de Mutsert R, Grootendorst DC, Indemans F, Boeschoten EW, Krediet RT, Dekker FW. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 2009; 19: 127-135.
15. Avram MM, Mittman N, Myint MM, Fein P et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357. (Pubitemid 34193126)
16. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779. (Pubitemid 38294808)
17. Souberbielle J-C, Boutten A, Carlier M-C et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350. (Pubitemid 44086584)
18. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-2302. (Pubitemid 28416556)
19. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de VernejoulMC. Association of bone activity, calciumload, aortic stiffness and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
20. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 2004; 19: i9-i13. (Pubitemid 38455637)
21. Adragao T, Herberth J, Monier-Faugere MC et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 450-455.
22. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861. (Pubitemid 24272045)
23. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
24. Schlieper G, Kruger T, Djuric Z et al. Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 2008; 74: 1582-1587.
25. Wang AY, Wang M, Woo J et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159-168. (Pubitemid 36032720)
26. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36: 51-62. (Pubitemid 44050610)
27. Bover J, Canal C, Marco H, Fernandez-Llama P, Bosch RJ, Ballarín J. Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder. Contrib Nephrol 2008; 161: 222-233.
28. Takahashi N, Kojima T, Ogawa H, Ishiguro N. Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients. Nephrology (Carlton) 2007; 12: 539-545. (Pubitemid 350059124)
29. Murakami R, Murakami S, Tsushima R et al. Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy. Nephrol Dial Transplant 2008; 23: 315-320. (Pubitemid 351767408)
30. Iwata Y, Wada T, Yokoyama H et al. Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med 2007; 46: 447-452. (Pubitemid 46629940)
31. Sugimoto T, Ritter C, Morrissey J et al. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 1990; 37: 1522-7. (Pubitemid 20198035)
32. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469. (Pubitemid 47208519)
33. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76: S1-S130